Methylphenidate: A treatment for Parkinson's disease?

CNS Drugs

Volumn 27, Issue 1, 2013, Pages 1-14

  Devos, David ^a,b   Moreau, Caroline ^b   Delval, Arnaud ^b   Dujardin, Kathy ^b   Defebvre, Luc ^b   Bordet, Regis ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; METHYLPHENIDATE; NORADRENALIN; PLACEBO;

APATHY; ARTICLE; ATTENTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DECREASED APPETITE; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG CONTRAINDICATION; ERECTILE DYSFUNCTION; FATIGUE; GAIT DISORDER; GASTRITIS; GASTROINTESTINAL PAIN; HEADACHE; HUMAN; INSOMNIA; NAUSEA; PAIN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE; VOMITING;

ANIMALS; ANTIPARKINSON AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HUMANS; METHYLPHENIDATE; PARKINSON DISEASE;

EID: 84873039517     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0017-y     Document Type: Article

References (73)

1. de Lau L, Breteler M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5:525-35.
2. Chaudhuri R, Schapira A. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464-74.
3. Singh N, Pillay V, Choonara YE. Advances in the treatment of Parkinson's disease. Prog Neurobiol. 2007;81:29-44.
4. Olanow C, Stern M, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72(Suppl. 4):S1-136.
5. Fox S, Lang A. l-dopa-related motor complications: phenomenology. Mov Disord. 2008;23(Suppl. 3):S509-14.
6. Factor S. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics. 2008;5:164-80.
7. Bonuccelli U, Del Dotto P, Rascol O. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism Relat Disord. 2009;15(Suppl. 4):S44-53.
8. Sethi K. Levodopa unresponsive symptoms in Parkinson disease. Mov Disord. 2008;23(Suppl. 3):S521-33.
9. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003;349:1925-34.
10. Soldani P, Fornai F. The functional anatomy of noradrenergic neurons in Parkinson's disease. Funct Neurol. 1999;14:97-109.
11. Zarow C, Lyness SA, Mortimer JA, et al. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337-41.
12. Chopin P, Colpaert FC, Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther. 1999;288:798-804.
13. Maertens de Noordhout A, Pepin JL, Delwaide PJ. Open study of tinazidine in the treatment of freezing gait. In: 11th International Symposium on Parkinson's disease, 1994 Mar 26-30, Rome.
14. Ogawa N, Yamamoto M, Takayama H. l-threo-3,4-dihydroxyphenylserine treatment of Parkinson's disease. J Med. 1985;16:525-34.
15. Narabayashi H, Yokochi F, Ogawa T, Igakura T. Analysis of l-threo-3,4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease. No To Shinkei. 1991;43:263-8.
16. Tohgi H, Abe T, Takahashi S. The effects of l-threo-3,4- dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm Park Dis Dement Sect. 1993;5:27-34.
17. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin and norepinephrine comparison with amphetamine. J Neurochem. 1997;68:2032-7.
18. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155:1325-31.
19. Nutt JG, Carter JH, Sexton GJ. The dopamine transporter: importance in Parkinson's disease. Ann Neurol. 2004;55:766-73.
20. Keating GM, McClellan K, Jarvis B. Methylphenidate (OROS formulation). CNS Drugs. 2001;15:495-500.
21. Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1397-409.
22. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121.
23. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology. 2009;57:608-18.
24. Gainetdinov RR, Jones SR, Fumagalli F, et al. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev. 1998;26:148-53.
25. Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord. 2003;18:872-83.
26. Overtoom CC, Verbaten MN, Kemner C, et al. Effects of methylphenidate, desipramine, and l-dopa on attention and inhibition in children with attention deficit hyperactivity disorder. Behav Brain Res. 2003;145:7-15.
27. Halliday AM, Dwivedi AK, Payne M, et al. Methylphenidate in Parkinsonism. BMJ. 1961; i:1652-5.
28. Bloem BR, Hausdorff JM, Visser JE, et al. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord. 2004;19:871-84.
29. Schaafsma JD, Balash Y, Gurevich T, et al. Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. Eur J Neurol. 2003;10:391-8.
30. Nutt JG, Bloem BR, Giladi N, et al. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol. 2011;10:734-44.
31. Mahabier W, Snijders AH, Delval A, et al. Freezing of gait. In: Kompoliti K, Verhagen Metman L, editors. Encyclopedia of movement disorders. Oxford: Academic Press; 2010. p. 486-91.
32. Giladi N. Medical treatment of freezing of gait. Mov Disord. 2008;23(Suppl. 2):S482-8.
33. Auriel E, Hausdorff JM, Giladi N. Methylphenidate for the treatment of Parkinson disease and other neurological disorders. Clin Neuropharmacol. 2009;32:75-81.
34. Pollak L, Dobronevsky Y, Prohorov T, et al. Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state. J Neural Transm Suppl. 2007;72:145-8.
35. Devos D, Krystkowiak P, Clement F, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78:470-5.
36. Espay AJ, Dwivedi AK, Payne M, et al. Methylphenidate for gait impairment in Parkinson's disease: a randomized clinical trial. Neurology. 2011;76:1256-62.
37. Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012;11:589-96.
38. Giladi N, Shabtai H, Simon ES, et al. Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism Relat Disord. 2000;6:165-70.
39. Snijders AH, Leunissen I, Bakker M, et al. Gait-related cerebral alterations in patients with Parkinson's disease with freezing of gait. Brain. 2011;134(Pt 1):59-72.
40. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry. 1992;149:443-54.
41. Warbutton JW. Depressive symptoms in Parkinson patients referred for thalamotomy. J Neurol Neurosurg Psychiatry. 1967;30:368-70.
42. Celesia GC, Wanamaker WM. Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst. 1972;33:577-83.
43. Marsch GG, Markham CG. Does levodopa alter depression psychopathology in Parkinsonism patients? J Neurol Neurosurg Psychiatry. 1973;36:925-35.
44. Klimek V, Stokmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci. 1997;17:8451-548.
45. Remy P, Doder M, Lees A, et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314-32.
46. Perez-Lloret S, Rascol O. Parkinson disease: serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol. 2012;8(7):365-6.
47. Richard IH, McDermontt MP, Kurlan R, et al. A randomized, double-blind placebo-controlled trial of antidepressants in Parkinson's disease. Neurology. 2012;78:1229-36.
48. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23:850-7.
49. Cantello R, Aguggia M, Gilli M, et al. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J Neurol Neurosurg Psychiatry. 1989;52:724-31.
50. Martin WR, Sloan JW, Sapira JD, et al. Physiologic subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther. 1971;12:245-58.
51. Persico AM, Riech S, Henningfield JE, et al. Parkinsonian patients report blunted subjective effects of methylphenidate. Exp Clin Psychopharmacol. 1998;6:54-63.
52. Evans AH, Lawrence AD, Lees AJ. Changes in psychomotor effects of l-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2009;80:267-72.
53. Schrag A, Leentjens AF. Parkinson disease: scales to detect depression in Parkinson disease. Nat Rev Neurol. 2012;8(7):359-60.
54. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3:243-54.
55. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord. 2008;23:1889-96.
56. Oguru M, Tachibana H, Toda K, et al. Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2010;23:35-41.
57. Dujardin K, Sockeel P, Delliaux M, et al. Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord. 2009;24:2391-7.
58. Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson's disease. Mov Disord. 2007;22:778-84.
59. Thobois S, Ardouin C, Lhommée E. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain. 2010;133:1111-27.
60. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2002;14:461-2.
61. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol. 2011;69:986-96.
62. Camicioli R, Lea E, Nutt JG, et al. Methylphenidate increases the motor effects of l-dopa in PD: a pilot study. Clin Neuropharmacol. 2001;24:208-13.
63. Hoogland J, de Bie RM, Williams-Gray CH, et al. Catechol-O- methyltransferase val158met and cognitive function in Parkinson's disease. Mov Disord. 2010;25:2550-4.
64. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26(Suppl. 3):S42-80.
65. Alves G, Wentzel-Larsen T, Larsen JP, et al. Is fatigue independent and persistent symptom in patients with Parkinson disease? Neurology. 2004;63:1908-11.
66. Nutt JG, Carter JH, Carlson NE. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Arch Neurol. 2007;64:319-23.
67. Mendonça DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord. 2007;22:2070-6.
68. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord. 2005;20:1557-63.
69. Cantello R, Aguggia M, Gilli M, et al. Analgesic action of methylphenidate on parkinsonian sensory symptoms: mechanisms and pathophysiological implications. Arch Neurol. 1988;45:973-6.
70. Aagaard L, Hansen EH. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat. 2011;7:729-44.
71. Savill N, Bushe CJ. A systematic review of the safety information contained within the summaries of product characteristics of medications licensed in the United Kingdom for attention deficit hyperactivity disorder: how does the safety prescribing advice compare with national guidance? Child Adolesc Psychiatry Ment Health. 2012;6(1):2.
72. National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder (ADHD). Diagnosis and management of ADHD in children, young people and adults: NICE National Institute for Health and Clinical Excellence clinical guideline 72, 2008 [online]. http://www.nice.org.uk/CG072. Accessed 26 Oct 2012.
73. Kurlan R. Tourette's syndrome: are stimulants safe? Curr Neurol Neurosci Rep. 2003;3:285-8.